Episode 16 - Closing Remarks

As the panel discussion concludes, Peter Salgo, MD; Jeffrey D. Dunn, PharmD, MBA; Yehuda Handelsman, MD, FACP, FACE, FNLA; Maria Lopes, MD, MS; and Kari Uusinarkaus, MD, FAAFP, FNLA, share their final insights about managed care models and clinical and economic outcomes in diabetes and obesity.

Dr Dunn says that he expects challenges to accompany changes in drug formularies, and notes that all stakeholders involved in a patient’s care need to understand the importance of risk stratification, preventive measures, integrative care, and pharmacist-centric medication therapy management.

Dr Handelsman adds that society needs to focus on preventive measures and their long-term benefits.

Dr Lopes and Dr Uusinarkaus explain that there is no one-size-fits-all approach to addressing the diabetes and obesity epidemics. The panelists conclude that innovative population-based solutions that place an emphasis on prevention need to be developed by society, government, and the various stakeholders in the healthcare field.

Related Videos
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Yael Mauer, MD, MPH
Pregnant Patient | image credit: pressmaster -
Dr Julie Patterson, National Pharmaceutical Council
Related Content
CH LogoCenter for Biosimilars Logo